Introduction
After kidney transplantation, rejection and drug-related toxicity occur despite tacrolimus whole-blood pre-dose concentrations ([Tac]blood) being within the target range. The tacrolimus concentration within peripheral blood mononuclear cells ([Tac]cells) might correlate better with clinical outcomes. The aim of this study was to investigate the correlation between [Tac]blood and [Tac]cells, the evolution of [Tac]- cells and the [Tac]cells/[Tac]blood ratio, and to assess the relationship between tacrolimus concentrations and the occurrence of rejection.
Methods
In this prospective study, samples for the measurement of [Tac]blood and [Tac]cells were collected on days 3 and 10 after kidney transplantation, and on the morning of a for-cause kidney transplant biopsy. Biopsies were reviewed according to the Banff 2019 update.
Results
Eighty-three [Tac]cells samples were measured of 44 kidney transplant recipients. The correlation between [Tac]cells and [Tac]blood was poor (Pearson’s r = 0.56 (day 3); r = 0.20 (day 10)). Both the dose-corrected [Tac]cells and the [Tac]cells/[Tac]blood ratio were not significantly different between days 3 and 10, and the median inter-occasion variability of the dose-corrected [Tac]cells and the [Tac]cells/[Tac]blood ratio were 19.4% and 23.4%, respectively (n = 24). Neither [Tac]cells, [Tac]blood, nor the [Tac]- cells/[Tac]blood ratio were significantly different between patients with biopsy-proven acute rejection (n = 4) and patients with acute tubular necrosis (n = 4) or a cancelled biopsy (n = 9; p > 0.05).
Conclusions
Tacrolimus exposure and distribution appeared stable in the early phase after transplantation. [Tac]cells was not significantly associated with the occurrence of rejection. A possible explanation for these results might be related to the low number of patients included in this study and also due to the fact that PBMCs are not a specific enough matrix to monitor tacrolimus concentrations.
References:
1. B.J. Nankivell, C.H. P’Ng, P.J. O’Connell, J.R. Chapman Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras Transplantation, 100 (2016), pp. 1723-1731.
2. J. Sellares, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence Am. J. Transplant., 12 (2012), pp. 388-399.
3. M. Brunet, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report Ther. Drug Monit., 41 (3) (2019), pp. 261-30.
4. LD.R. Kuypers, K. Claes, P. Evenepoel, B. Maes, Y. Vanrenterghem Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients Clin. Pharmacol. Ther., 75 (2004), pp. 434-447.
5. S. Salcedo-Herrera, J.L. Pinto Ramirez, A. García-Lopez, J. Amaya-Nieto, F. Girón-Luque Acute rejection in kidney transplantation and early beginning of tacrolimus Transplant Proc, 51 (6) (2019), pp. 1758-1762.
6. A. Capron, V. Haufroid, P. Wallemacq Intra-cellular immunosuppressive drugs monitoring: A step forward towards better therapeutic efficacy after organ transplantation? Pharmacol. Res., 111 (2016), pp. 610-618.
7. S.S. Han, et al. Monitoring the intracellular tacrolimus concentration in kidney transplant recipients with stable graft function PLoS ONE, 11 (4) (2016), p. E0153491.
8. T. van Gelder, J. Klupp, T. Sawamoto, U. Christians, R.E. Morris ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implication Transplant Proc, 33 (3) (2001), pp. 2420-2421.
9. H. Zahir, R.A. Nand, K.F. Brown, B.N. Tattam, A.J. McLachlan Validation of methods to study the distribution and protein binding of tacrolimus in human blood J. Pharmacol. Toxicol. Methods, 46 (1) (2001), pp. 27-350.
10. R. Venkataramanan, et al. Pharmacokinetics of FK 506 in transplant patients Transplant Proc, 23 (1991), pp. 2736-2740.
11. R. Venkataramanan, et al. Clinical pharmacokinetics of tacrolimus Clin. Pharmacokinet., 29 (6) (1995), pp. 404-430.
12. R.A. Klaasen, et al. Longitudinal study of tacrolimus in lymphocytes during the first year after kidney transplantation Ther. Drug Monit., 40 (5) (2018), pp. 558-566.
13. D. Pensi, et al. First UHPLC-MS/MS method coupled with automated online SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients J. Mass Spectrom., 52 (3) (2017), pp. 187-195.
